26/03/2026
[EUROGIN 2026 - PARTENARIAT avec Recurrent Respiratory Papillomatosis Foundation ]
Nous sommes fières que Giulia ait représenté Vaincre PRR lors du congrès EUROGIN, aux côtés de Kim Mcclellan RRPF. Cette rencontre a été une excellente occasion de renforcer nos liens et de construire ensemble des projets pour les malades.
L’intervention de Kim a rappelé que la perspective des malades reste trop souvent absente des grandes conférences médicales, alors qu’elle est essentielle : la PRR, souvent qualifiée à tort de « bénin », peut nécessiter de nombreuses chirurgies, affecter la respiration, la voix et la vie sociale et professionnelle et comporte un risque de transformation maligne. Partager ces voix humanise la vision des professionnels et favorise le progrès scientifique.
Aujourd’hui, la recherche s’accélère grâce à l’IA et aux grandes bases de données, les nouvelles immunothérapies commencent à être disponibles aux États-Unis, et le vaccin reste la voie principale pour lutter contre les HPV.
Plusieurs publications et sessions ont été entièrement dédiées àla PRR, confirmant que la mobilisation scientifique se poursuit.
Ensemble, Vaincre PRR, RRPF (USA) et Stichting RRP (Pays-Bas) unissent leurs forces pour sensibiliser, soutenir les patients et faire avancer la recherche.
RRPF President Kim McClellan was invited to Vienna, Austria, by Merck to speak at EUROGIN 2026, the world's leading international congress on HPV infections and associated cancers.
It remains rare for the patient perspective to be included at major medical conferences, making this an extraordinary opportunity to elevate awareness of Recurrent Respiratory Papillomatosis (RRP) on a global stage.
Kim's presentation, "HPV in the Airway: The Often Overlooked Burden of Recurrent Respiratory Papillomatosis," challenged long-standing misconceptions about the disease.
RRP is too often labeled as "benign" or "low-risk" — but the reality for patients tells a very different story. RRP can require dozens, sometimes hundreds, of surgeries over a lifetime, significantly impacting breathing, voice, and daily life — and it carries a meaningful risk of malignant transformation.
One of the most powerful moments came when Kim shared direct patient voices — what individuals living with RRP wish their clinicians truly understood. The impact was immediate: the keynote speaker who followed referenced these points and stated it was time to stop calling RRP "low risk."
As Kim reflected, "That moment underscored why patient voices matter: they change narratives, and they drive progress."
The conference also highlighted exciting scientific advancements, including a presentation on the investigational immunotherapy Papzimeos, a newly developed treatment algorithm for adult RRP, and critical insights on HPV typing and vertical transmission.
Kim also connected with global advocates, including Giulia Barina from Vaincre PPR in France — a reminder that progress is strongest when driven by a united, international community.
"We are making RRP impossible to ignore — and that is how we move closer to ending it."
🔬 Learn more about RRP and how you can support the mission at rrpf.org